HCR 579 Module 7 Ethical Paper: Precision Medicine Example

Precise for Whom? Fairness, Findings and Consent in Precision Medicine

Student Name

MS in Regulatory Science, Arizona State University

HCR 579: Translational Research in Drug Discovery and Development

Instructor Name

Month Day, Year

Precise for Whom? Fairness, Findings and Consent in Precision Medicine

Introduction

Precision medicine promises the right treatment for the right patient based on genetic and molecular information. Its ethical risks are often framed as privacy. This paper argues that the larger risk is unfairness: that precision tools work best for the people best represented in the data and best connected to the centers that use them.

The Data Problem

Genomic medicine depends on reference data. When variants are interpreted against databases dominated by one ancestry, results are more reliable for that group and less reliable for others. A 2016 analysis found that participants in genome-wide association studies were overwhelmingly of European ancestry, with only modest progress for other groups (Popejoy & Fullerton, 2016). For a patient of African or Indigenous ancestry, a tumor or germline variant is more likely to be labeled of uncertain significance, which can mean no actionable result.

The Access Problem

Precision oncology requires tumor sequencing, often a fresh biopsy and access to targeted drugs or trials. These resources concentrate at academic centers. National genomic matching trials have shown that testing is feasible across large networks (Flaherty et al., 2020), but patients in rural areas or safety-net hospitals may never be tested, and insurance coverage for comprehensive sequencing varies. The result can be a two-tier system in which some patients are matched to targeted therapy and others never learn they could have been.

Incidental Germline Findings

Tumor sequencing can reveal inherited variants, such as those in BRCA1 or BRCA2, that matter for the patient's family as well as for treatment. Patients must decide in advance whether they want such findings, and clinicians need a plan for confirmatory germline testing and genetic counseling. Returning findings without counseling can cause harm; withholding clinically actionable findings can deny relatives prevention.

Consent

Consent for precision medicine must explain sequencing, the chance of no actionable result, possible germline findings, data sharing and future research use. Long, technical forms satisfy regulations but may not produce understanding. The course text emphasizes that translational research depends on participants' trust (Shah & Wells, 2020), and that trust depends on consent people can actually follow.

Remedies

Counterargument

Some argue that precision medicine should proceed as fast as possible and that equity will follow as costs fall. History suggests otherwise: technologies introduced unequally tend to entrench gaps. Building fairness into design costs less than repairing inequity later.

Conclusion

Precision medicine is only as precise as its data and only as fair as its access. Diverse databases, broad coverage, community partnerships, careful handling of germline findings and consent people understand would let its benefits reach the patients it is meant to serve.

References

Flaherty, K. T., Gray, R., Chen, A., Li, S., Patton, D., Hamilton, S. R., Williams, P. M., Mitchell, E. P., Iafrate, A. J., Sklar, J., Harris, L. N., McShane, L. M., Rubinstein, L. V., Sims, D. J., Routbort, M., Coffey, B., Fu, T., Zwiebel, J. A., Little, R. F., . . . NCI-MATCH Team. (2020). The Molecular Analysis for Therapy Choice (NCI-MATCH) trial: Lessons for genomic trial design. Journal of the National Cancer Institute, 112(10), 1021-1029. https://doi.org/10.1093/jnci/djz245

Popejoy, A. B., & Fullerton, S. M. (2016). Genomics is failing on diversity. Nature, 538(7624), 161-164. https://doi.org/10.1038/538161a

Shah, K. P., & Wells, C. E. (2020). Translational research in drug discovery and development: A Top Hat interactive text. Top Hat Monocle.